Technical Analysis for ORIC - Oric Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 8.99 | 0.67% | 0.06 |
ORIC closed up 0.67 percent on Friday, May 31, 2024, on 2.12 times normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
Earnings due: Jun 12
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
Shooting Star Candlestick | Bearish | 0.00% | |
Lizard Bearish | Bearish Day Trade Setup | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Doji - Bearish? | Reversal | 0.00% | |
Stochastic Buy Signal | Bullish | 0.67% | |
Bollinger Band Squeeze | Range Contraction | 0.67% | |
Gapped Up | Strength | 0.67% | |
Oversold Stochastic | Weakness | 0.67% |
Alert | Time |
---|---|
20 DMA Resistance | 1 day ago |
Up 3% | 1 day ago |
Rose Above 20 DMA | 1 day ago |
Up 2% | 1 day ago |
Rose Above Previous Day's High | 1 day ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/12/2024
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatment Treatment Of Cancer Oncology Chemotherapy Antineoplastic Drugs Occupational Safety And Health Precision Medicine Specialty Drugs Cancer Therapeutics Cd73
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatment Treatment Of Cancer Oncology Chemotherapy Antineoplastic Drugs Occupational Safety And Health Precision Medicine Specialty Drugs Cancer Therapeutics Cd73
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 16.63 |
52 Week Low | 5.07 |
Average Volume | 459,031 |
200-Day Moving Average | 9.32 |
50-Day Moving Average | 9.98 |
20-Day Moving Average | 9.10 |
10-Day Moving Average | 8.88 |
Average True Range | 0.56 |
RSI (14) | 46.52 |
ADX | 20.23 |
+DI | 18.94 |
-DI | 20.83 |
Chandelier Exit (Long, 3 ATRs) | 8.46 |
Chandelier Exit (Short, 3 ATRs) | 10.02 |
Upper Bollinger Bands | 9.76 |
Lower Bollinger Band | 8.44 |
Percent B (%b) | 0.42 |
BandWidth | 14.54 |
MACD Line | -0.29 |
MACD Signal Line | -0.35 |
MACD Histogram | 0.058 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 9.57 | ||||
Resistance 3 (R3) | 9.61 | 9.46 | 9.47 | ||
Resistance 2 (R2) | 9.46 | 9.32 | 9.44 | 9.44 | |
Resistance 1 (R1) | 9.23 | 9.23 | 9.15 | 9.18 | 9.41 |
Pivot Point | 9.08 | 9.08 | 9.04 | 9.06 | 9.08 |
Support 1 (S1) | 8.84 | 8.93 | 8.77 | 8.80 | 8.57 |
Support 2 (S2) | 8.69 | 8.84 | 8.67 | 8.54 | |
Support 3 (S3) | 8.46 | 8.69 | 8.51 | ||
Support 4 (S4) | 8.41 |